Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized
            controlled trial

Müller, Eduardo Gayger; Santos, Myrna Serapião dos; Freitas, Denise de; Gomes, José Álvaro Pereira; Belfort, Rubens

doi:10.5935/0004-2749.20170038

Cited by 23 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[150][151][152] Tacrolimus drops/ointment 0.03% is used for children 2 years to 15 years old; either 0.03% or 0.1% is used for patients 16 years and older. 153 Randomized clinical trials have demonstrated the efficacy of topical tacrolimus 0.1% applied conjunctivally in patients who had failed conjunctivitis therapy with topical corticosteroids, cyclosporine, and/or antiallergy medications. 154 These agents may make patients more susceptible to herpes simplex keratitis.…”

Section: Management Preventionmentioning

confidence: 99%

Conjunctivitis Preferred Practice Pattern®

Varu¹,

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Management Preventionmentioning

confidence: 99%

Conjunctivitis Preferred Practice Pattern®

Varu¹,

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The eye rubbing frequency was assessed on a scale ranging from 1 to 5, where 1 represents no eye rubbing, and 5 represents constant eye rubbing [3,21]. Signs of conjunctival hyperemia, swelling, papillae, and corneal epithelial disorder were assessed and graded by severity from 0 (no corresponding signs) to 3 (serious signs) by the clinician [22][23][24].…”

Section: Evaluation Of Clinical Manifestations In Ac Patientsmentioning

confidence: 99%

Corneal biomechanical changes in allergic conjunctivitis

Wang

Deng

et al. 2021

Eye and Vis

View full text Add to dashboard Cite

Background To explore corneal biomechanical changes, identify related factors and determine early indicators of keratoconus (KC) development risk in allergic conjunctivitis (AC) patients. Methods A total of 50 patients, including 20 eyes without AC and 30 eyes with AC were enrolled in this study. All patients underwent a complete ocular examination, including evaluations of clinical manifestations of AC, corneal tomography and densitometry by Pentacam, corneal biomechanics by Corvis ST, and corneal and epithelial thickness mapping by RTvue optical coherence tomography (OCT). Results The index of surface variance (ISV), index of vertical asymmetry (IVA), keratoconus index (KI), index of height decentration (IHD) and Belin/Ambrosio enhanced ectasia total deviation index (BAD-D) were significantly higher in the AC group than in the non-allergic conjunctivitis (NAC) group (P < 0.05). The tomography and biomechanical index (TBI) was also significantly higher in the AC group (P = 0.04). The average epithelial thickness in the 2–7 mm annulus was significantly thinner in the AC group than in the NAC group (P < 0.05). The average densitometry of the total cornea and the anterior layer were higher in the AC group than in the NAC group (P < 0.001). The ISV, IVA, KI, IHD and BAD-D were significantly correlated with the TBI and changes in corneal epithelial thickness in AC patients (P < 0.05). The changes in epithelial thickness were closely related to the eye rubbing frequency and allergic sign scores (P < 0.05). Conclusions AC patients should be advised to routinely undergo corneal tomographic and biomechanical measurements, and the TBI could be used as an indicator of KC development risk in AC patients. Trial registration Corneal Biomechanical Changes of Allergic Conjunctivitis, NCT04299399. Registered March 3, 2020 - Retrospectively registered.

show abstract

“…In a publication released in 2017, the safety and side effects of Tacrolimus eye drop were evaluated in human vernal keratoconjunctivitis and the Tacrolimus eye drop alleviated the clinical symptoms of limbal inflammatory activity and keratitis during the course of treatment. 7 In this study there were no statistical differences between the group receiving Tacrolimus eye drops and the control group in terms of limbal inflammation incidence and other pathological changes.…”

Section: Discussionmentioning

confidence: 49%

“…Correspondence: Malihe Nikandish Ophthalmology Department, Valiasr Hospital, Birjand University of Medical Sciences, P. O. Box:9717853577, Birjand, Iran Tel +9856 32395000 Fax +9856 32430076 Email malihenikandish@yahoo.com keratoconjunctivitis, 7 atopic keratoconjunctivitis, 8 keratoconjunctivitis sicca (KCS), 9 and giant papillary conjunctivitis. 10 Previous studies on the use of topical Tacrolimus have shown good levels of effectiveness in the improvement of ocular symptoms, with no significant adverse effects.…”

Section: Vernalmentioning

confidence: 99%

Preliminary In Vivo Safety Evaluation of a Tacrolimus Eye Drop Formulation Using Hydroxypropyl Beta Cyclodextrin After Ocular Administration in NZW Rabbits

Mahmoudi¹,

Malaekeh‐Nikouei²,

Hanafi‐Bojd³

et al. 2020

OPTH

View full text Add to dashboard Cite

Aim: Tacrolimus is an immunosuppressive drug with higher potency compared to cyclosporine A (as a useful immunosuppressant). We prepared an ophthalmic solution formulation of Tacrolimus using hydroxypropyl beta cyclodextrin (HP-ßCD). In the present study, safety of this formulation was investigated in rabbits. Materials and Methods: Formulation containing HP-ßCD, Tacrolimus, Polyvinyl alcohol (PVA) and Benzalkonium Chloride in PBS 7.4 was prepared. Tacrolimus concentration in ophthalmic preparation was 0.05% w/v. Ten male New Zealand white rabbits were housed in clean separated cages. One drop of Tacrolimus prepared formulation and a placebo formulation were applied every 12 hrs in the right and left eyes respectively, for 28 days. Results: This new aqueous formulation of Tacrolimus could improve Tacrolimus solubility about 42 times. Clinical examinations on the 1st, 3rd, 7th, 14th and 28th days of study showed transient redness and conjunctivitis in some cases of both control and intervention groups that was not persistent. At the end of the study, there were no statistical differences between the two groups in corneal epithelial defect, redness or pathological evaluations. Conclusion: The results of this study suggest that eye drop formulation of CD-Tacrolimus is safe in preliminary evaluations and can be useful for further studies.

show abstract

Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial

Abstract: Treatment with tacrolimus was superior to sodium cromoglycate when comparing severity scores for symptoms of itching, foreign body sensation, and photophobia, as well as for signs of limbal inflammatory activity and keratitis.

Cited by 23 publications

References 0 publications

Conjunctivitis Preferred Practice Pattern®

Conjunctivitis Preferred Practice Pattern®

Corneal biomechanical changes in allergic conjunctivitis

<p>Preliminary I<em>n</em> V<em>ivo</em> Safety Evaluation of a Tacrolimus Eye Drop Formulation Using Hydroxypropyl Beta Cyclodextrin After Ocular Administration in NZW Rabbits</p>

Contact Info

Product

Resources

About